Kumar Singh Saikatendu, the Director of the Drug Discovery Sciences Group at Takeda Pharmaceuticals briefly outlines the “Emerging targets of SARS-CoV-2 replication complex” in his introduction to the afternoon session on emerging strategies for targeting coronaviruses.
Part of the NIBR Science of Therapeutics Symposium on Coronavirus Antivirals, June 8, 2021. Content presented by external speakers not affiliated with Novartis are responsible for their own content and do not speak on behalf of Novartis.
©2021 Novartis AG
Source Novartis YouTube
